Charts
3750:ＡＤＲ１２０Ｓ
Remove from History
Add to History
HistoryはJSONファイルなのですが、障害が発生したのでとりあえず登録者をログインユーザーに限定しています。
Current:
797.0
PreviousClose:
805.0
Open:
808.0
High:
808.0
Low:
796.0
Dividend History None
2020-03:
10.0
EPS:
-44.47
BPS:
2.464
ROA:
-29.0%
ROE:
-121.5%
ADR Biomedical Holdings Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications, including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, meniscus repair, stress urinary incontinence scleroderma, vocal cord repair, liver cirrhosis, etc. In addition, it invests in, owns, develops, leases, and manages real estate projects and hotels; and provides real estate brokerage services. The company was formerly known as ADR120S, Inc. and changed its name to ADR Biomedical Holdings Inc. in July 2026. ADR Biomedical Holdings Inc. was incorporated in 2004 and is headquartered in Chiyoda, Japan.